Clinical outcomes in a cohort of patients with heparin‐induced thrombocytopenia
Authors:
Open Access
- 7 April 2017
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 92 (8) , 730-738
Abstract
Background: Heparin‐induced thrombocytopenia (HIT) is a thrombotic disorder usually prompting treatment with non‐heparin anticoagulants. The benefits and risks of such treatments have not been fully assessed.Methods: We analyzed data for 442 patients having a positive heparin‐platelet factor 4 antibody test and recent heparin exposure. The primary outcome was a composite endpoint (death, limb amputation/gangrene, or new thrombosis). Secondary outcomes included bleeding and the effect of anticoagulation.Findings: Seventy‐one patients (16%) had HIT with thrombosis (HIT‐T); 284 (64%) had HIT without thrombosis (isolated HIT); 87 (20%) did not have HIT. An intermediate or high “4T” score was found in 85%, 58%, and 8% of the three respective groups. Non‐heparin anticoagulation was begun in 80%, 56%, and 45%. The composite endpoint occurred in 48%, 36%, and 17% (P = .01) of which 61%, 38%, and 40% were receiving non‐heparin anticoagulation. Compared with the no HIT group, the composite endpoint was significantly more likely in HIT‐T [HR 2.48 (1.35‐4.55), P = .003)] and marginally more likely in isolated HIT [HR 1.66 (0.96‐2.85), P = .071]. Importantly, risk increased (HR 1.77, P = .02) after platelet transfusion. Major bleeding occurred in 48%, 36%, and 16% of the three groups (P = .005). Non‐heparin anticoagulation was not associated with a reduction in composite endpoint events in either HIT group.Interpretation: HIT patients have high risks of death, limb amputation/gangrene, thrombosis, and bleeding. Non‐heparin anticoagulant treatment may not benefit all patients and should be considered only after careful assessment of the relative risks of thrombosis and bleeding in individual patients.Keywords
Funding Information
- NHLBI (HL072290, HL072033, HL072291, HL072196, HL072289, HL072191, HL072299, HL072305, HL072274, HL072028, HL072359, HL072072, HL072355, HL072346, HL072331, HL072268)
- National Institutes of Health
This publication has 14 references indexed in Scilit:
- Heparin-Induced ThrombocytopeniaNew England Journal of Medicine, 2015
- Treatment and Prevention of Heparin-Induced ThrombocytopeniaChest, 2008
- Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settingsJournal of Thrombosis and Haemostasis, 2006
- Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990sThrombosis Research, 2006
- Lepirudin in patients with heparin-induced thrombocytopenia – results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3Journal of Thrombosis and Haemostasis, 2005
- Thrombosis and ELISA optical density values in hospitalized patients with heparin‐induced thrombocytopeniaJournal of Thrombosis and Haemostasis, 2004
- Argatroban Anticoagulant Therapy in Patients With Heparin-Induced ThrombocytopeniaCirculation, 2001
- Lepirudin (Recombinant Hirudin) for Parenteral Anticoagulation in Patients With Heparin-Induced ThrombocytopeniaCirculation, 1999
- Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced ThrombocytopeniaCirculation, 1999
- A 14-year study of heparin-induced thrombocytopeniaThe American Journal of Medicine, 1996